BridgeBio Oncology Therapeutics, Inc.

BBOT Nasdaq SEC CIK 1869105
Follow BridgeBio Oncology Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$34.2M +23.6% vs same quarter last year
EPS, diluted −$0.43 +58.3% vs same quarter last year
Operating cash flow −$28.4M +1.4% vs same quarter last year
Operating income −$37.5M +23.8% vs same quarter last year
Net income by quarter
−$19.7M
−$22.1M
−$28.4M
−$44.8M
−$38.8M
−$42.1M
−$56.5M
−$34.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
−$150M−$100M−$50M$0FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$134M
FY24−$74.3M
FY23−$41.7K
FY22-